Table 1.

Baseline characteristics of participants, stratified by prostate cancer grade and treatment arm, in the PCPT

FinasteridePlacebo
ControlTotala cancerCase Gleason 2–6Gleason 7–10ControlTotal cancerCase Gleason 2–6Gleason 7–10
(n = 743)(n = 708)(n = 422)(n = 257)Pb(n = 1,009)(n = 975)(n = 735)(n = 204)Pb
Age at baseline, mean (SD)63.6 (5.6)63.9 (5.6)63.4 (5.5)64.7 (5.7)0.2463.6 (5.6)63.6 (5.5)63.3 (5.4)64.5 (5.5)Frequency matched
 55–59, n (%)200 (26.9)184 (26.0)123 (29.1)55 (21.4)0.96270 (26.8)259 (26.6)212 (28.8)39 (19.1)1.00
 60–64240 (32.3)226 (31.9)135 (32.0)81 (31.5)330 (32.7)320 (32.8)241 (32.8)71 (34.8)
 65–69180 (24.2)175 (24.7)101 (23.9)67 (26.1)244 (24.2)238 (24.4)175 (23.8)49 (24.0)
 70+123 (16.6)123 (17.4)63 (14.9)54 (21.0)165 (16.3)158 (16.2)107 (14.6)45 (22.1)
Racec, n (%)
 White541 (72.8)655 (92.5)392 (92.9)234 (91.1)<0.0001848 (84.0)906 (92.9)693 (94.3)180 (88.2)<0.0001
 Black101 (13.6)35 (4.9)23 (5.5)12 (4.7)71 (7.0)46 (4.7)24 (3.3)19 (9.3)
 Other101 (13.6)18 (2.5)7 (1.7)11 (4.3)90 (8.9)23 (2.4)18 (2.4)5 (2.5)
BMI, mean (SD)27.6 (4.0)27.5 (3.8)27.3 (3.8)27.8 (3.8)0.5527.6 (4.0)27.4 (4.1)27.2 (4.1)28.3 (4.1)0.27
 Normal (BMI <25), n (%)200 (26.9)189 (26.7)121 (28.7)62 (24.1)0.91244 (24.2)282 (28.9)225 (30.6)45 (22.1)0.05
 Overweight (BMI 25 to <30)377 (50.7)354 (50.0)211 (50.0)130 (50.6)549 (54.4)502 (51.5)379 (51.6)102 (50.0)
 Obese (BMI ≥ 30)166 (22.3)165 (23.3)90 (21.3)65 (25.3)216 (21.4)191 (19.6)131 (17.8)57 (27.9)
Any supplement use, n (%)311 (50.7)285 (49.8)163 (48.7)116 (53.7)0.75423 (50.6)430 (54.4)326 (55.0)88 (53.0)0.12
Cholesterol mg/dL, mean (SD)216.0 (37.7)216.8 (40.7)216.1 (35.9)217.3 (45.3)0.71212.0 (39.5)215.2 (37.1)215.5 (36.9)214.7 (37.0)0.06
Family history, n (%)165 (22.2)155 (21.9)100 (23.7)50 (19.5)0.89207 (20.5)198 (20.3)154 (21.0)44 (21.6)Frequency matched
Diabetes, n (%)56 (7.5)37 (5.2)17 (4.0)18 (7.0)0.0771 (7.0)39 (4.0)25 (3.4)12 (5.9)<0.01
Smoking status, n (%)
 Never smoker257 (34.6)243 (34.3)160 (37.9)78 (30.4)0.84345 (34.2)356 (36.5)270 (36.7)75 (36.8)0.45
 Current smoker57 (7.7)49 (6.9)26 (6.2)20 (7.8)77 (7.6)65 (6.7)53 (7.2)11 (5.4)
 Former smoker429 (57.7)416 (58.8)236 (55.9)159 (61.9)587 (58.2)554 (56.8)412 (56.1)118 (57.8)
Diagnosed on a for-cause biopsy80 (10.8)342 (48.3)158 (37.4)167 (65.0)<0.0001107 (10.6)430 (44.1)287 (39.0)124 (60.8)<0.0001
T stage
 T1a92 (13.2)66 (15.9)18 (7.0)137 (14.1)107 (14.6)13 (6.4)
 T1b46 (6.6)29 (7.0)16 (6.2)72 (7.4)58 (7.9)12 (5.9)
 T1c358 (51.4)221 (53.4)130 (50.6)517 (53.3)403 (55.1)109 (53.7)
 T2a113 (16.2)60 (14.5)45 (17.5)123 (12.7)92 (12.6)27 (13.3)
 T2b39 (5.6)19 (4.6)19 (7.4)48 (4.9)26 (3.6)18 (8.9)
 T2c25 (3.6)9 (2.2)16 (6.2)43 (4.4)24 (3.3)18 (8.9)
 T315 (2.2)3 (0.7)11 (4.3)9 (0.9)4 (0.5)4 (2.0)
  • aThe number of high-grade and low-grade cancers does not equal the total number of cancer cases, due to the inclusion of ungraded cancers.

  • bComparison between controls and total cancer cases.

  • cNon-white controls were oversampled.